Drug Discovery

#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

How technology and science are driving neuroscience

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

#Alzheimer's #Alzheimer's Drug Discovery Foundation #Biomarkers #Drug discovery #Parkinson's #Partnership #The Michael J Fox Foundation #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

US$5m partnership targets Alzheimer’s and Parkinson’s biomarkers

The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More

#News

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #CNS #Collaboration #Drug discovery

Insilico Medicine and CMS announce CNS disease collaboration 

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration.   The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More

#News

Cell and gene therapy
#Drug discovery #Gene therapy #Metabolic diseases #Preclinical development

Study proves preclinical efficacy of gene therapy for metabolic disorder 

Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has revealed preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat metabolic disorder methylmalonic acidemia (MMA).  The findings, published in the Journal of Hepatology, show that a single systemic administration of a lentiviral vector… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Webinar

Watch now: Real-time chemistry coordination for modern drug discovery

In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More

#News

#Cambridge Omics Centre #Drug discovery #Metabolomics #Multiomics #Novogene Europe

Novogene Europe launches untargeted metabolomics service

Multiomics research services partner Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the UK and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome and broader life science studies. Untargeted Metabolomics… Read More

#News

Neural networks
#AI / data analytics / healthtech / informatics #Cancer Research Horizons #Drug discovery #Francis Crick Institute #Medicines Discovery Catapult (MDC)

National programme to support data-driven health start-ups 

Applications have opened for a national accelerator programme supporting data-driven health innovation.  KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine. … Read More

#News

Neuroscience Parkinson's disease
#Biology #Drug discovery #Neuroscience #Parkinson's

Parkinson’s disease and CDNF: Turning a neurotrophic factor into a viable therapy 

Henri Huttunen CSO of Herantis Pharma discusses the challenges of using neurotrophic factors as a treatment for Parkinson’s disease.   Many successful drugs originate from molecules that already exist within the human body. Hormones, neurotransmitters and other endogenous molecules perform essential biological functions, making them attractive starting points for therapeutic development. Read More

#Exclusive Content

FDA headquarters
#Biopharma #Drug development #FDA #Interview #Regulatory #United States

Is it harder to align with FDA expectations within pharma in 2026?  

DDW Editor Reece Armstrong speaks to David Crean, Chief Business Officer of biopharmaceutical company MediciNova, about recent turmoil within the FDA and what the pharma sector should expect from the agency going forward.  It’s been a volatile couple of years for the United States. President Trump’s second term… Read More

#Exclusive Content

Breast cancer research
#Breast cancer #Clinical development #Drug discovery #Partnership #Preclinical development

Astex partners with Genentech on breast cancer treatments 

Pharmaceutical company Astex has entered an exclusive worldwide research agreement with Genentech to identify treatments for breast cancer.  The partnership will aim to find small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer, leveraging Astex’s fragment-based drug discovery programme.  Under the terms of… Read More

#News

GBP pound sterling funding
#Antibodies #Drug discovery #Investment

Alchemab receives £25 million from British Business Bank 

Biotech Alchemab Therapeutics has extended its series A financing with a £25 million ($34 million) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date.   The company says the funding will enable it to build its clinical pipeline and grow its antibody dataset to more… Read More

#News

#Drug discovery #Drug Discovery Innovators & Investors #Events #Innovation #Innovators & Investors #Investment

Introducing the Drug Discovery Innovators & Investors Event Series

We’re excited to announce the launch of Drug Discovery Innovators & Investors (DDII) – a new event series from Drug Discovery World. The three-part global event series focuses on technology, innovation, and investment in early-stage drug discovery. Bringing together senior executives, R&D leaders, lab managers, and decision-makers from pharma and… Read More

#Editor's Choice #News